含膦酸酯结构的异噁唑酰胺衍生物的设计、合成及抗菌活性

doi:10.6023/cjoc202512004

研究论文

含膦酸酯结构的异噁唑酰胺衍生物的设计、合成及抗菌活性

佘慧娴, 汪晴, 查琴, 杨家强^*

遵义医科大学药学院, 贵州省化学药物创制全省重点实验室, 遵义 563000

收稿日期:2025-12-03 修回日期:2026-01-11
基金资助:
贵州省科技计划(黔科合基础-ZK[2024]一般265)和国家级大学生创新创业训练计划(202510661273)资助项目.

Design, Synthesis and Antibacterial Activities of Isoxzoleamide Derivatives Containing Phosphonate Fragment

She Huixian, Wang Qing, Zha Qin, Yang Jiaqiang^*

Guizhou Provincial Key Laboratory of Innovation and Manufacturing for Pharmaceuticals, School of Pharmacy, Zunyi Medical University, Zunyi 563000

Received:2025-12-03 Revised:2026-01-11
Contact: ^*E-mail:yjqcn@126.com
Supported by:
Guizhou Provincial Science and Technology Plan (No. Qiankehe Foundation ZK[2024]265) and the National College Students' innovation and entrepreneurship training program(No. ZYDC202402285).

文章分享

1. cjoc202512004辅助材料.pdf(764KB)

摘要/Abstract

为了获取抗菌候选化合物,运用分子杂合策略,将甲基异噁唑和膦酸酯结构通过酰胺键组合,设计合成了18个含膦酸酯结构的异噁唑酰胺衍生物,经¹H NMR, ¹³C NMR和元素分析确证其结构。抗菌活性测试结果表明,该类衍生物对所测细菌均有不同程度的抑制作用,尤其是对革兰氏阴性菌活性较显著,以二乙基((3-(2-氯-6-氟苯基)-5-甲基异噁唑-4-甲酰胺基)(对羟苯基)甲基)膦酸酯(Ⅲl)的活性最为突出,对大肠杆菌(E. coli)和耐氟喹诺酮大肠杆菌(FREC)的最小抑菌浓度(MIC)均为2 μg/mL,优于对照药庆大霉素,且不易产生耐药;时间-杀菌曲线显示,化合物Ⅲl在浓度≥1MIC时,对E. coli整个生长周期均有杀菌作用,尤其是在4MIC,效果最为明显;胞内杀菌实验表明化合物Ⅲl对感染巨噬细胞E. coli具有胞内杀菌活性;同时,化合物Ⅲl对小鼠单核巨噬细胞无毒性,可作为抗菌先导化合物深入研究。

关键词: 膦酸酯, 异噁唑, 酰胺衍生物, 合成, 抗菌活性

In order to obtain antibacterial candidate compounds, eighteen isoxazoleamide derivatives containing phosphonate fragment were designed and synthesized by combining methylisoxazole and phosphonate via amide bonds based on molecular hybridization strategy. Their structures were confirmed by ¹H NMR, ¹³C NMR and elemental analysis. Antibacterial activity tests revealed that these derivatives exhibited varying degrees of inhibition against the tested bacteria, with particularly significant activity against Gram-negative bacteria. Diethyl ((3-(2-chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxamido) (4-hydroxyphenyl)methyl)phosphonate(Ⅲl) stood out as the most potent, showing minimum inhibitory concentrations (MIC) of 2 μg/mL against both E. coli and FREC, outperforming the control drug gentamicin. Additionally, compound Ⅲl demonstrated a low tendency to induce resistance. Time-kill curve analysis indicated that at concentrations ≥1MIC, compound Ⅲl exhibited bactericidal effects throughout the growth cycle of E. coli, with the most pronounced effect observed at 4×MIC. Intracellular bactericidal assays confirmed that compound Ⅲl possesses intracellular antibacterial activity against E. coli-infected macrophages. Furthermore, compound Ⅲl showed no toxicity toward murine mononuclear macrophages, suggesting its potential as a promising lead compound for further antibacterial development.

Key words: phosphonateptide, isoxazole, amide derivatives, synthesis, antibacterial activities

引用此文

佘慧娴, 汪晴, 查琴, 杨家强. 含膦酸酯结构的异噁唑酰胺衍生物的设计、合成及抗菌活性[J]. 有机化学, doi: 10.6023/cjoc202512004.

She Huixian, Wang Qing, Zha Qin, Yang Jiaqiang. Design, Synthesis and Antibacterial Activities of Isoxzoleamide Derivatives Containing Phosphonate Fragment[J]. Chinese Journal of Organic Chemistry, doi: 10.6023/cjoc202512004.

导出引用 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

分享此文

参考文献

[1] Peng X. M.; Damu G. L. V.; Zhou, H. C. Curr. Pharm. design,2013, 19, 3884.
[2] Khursheed A.; Jain, V. Nat. Prod. J.,2021, 11, 648.
[3] Chikkula K. V.; Raja S.Int. J. Pharm. Pharm. Sci., 2017: 13-24.
[4] Ding Y.; Li Q. H.; Zhao Z. G.; Yang X. J.; Chen, F. Chin. J. Org. Chem.,2017, 37, 3282(in Chinese).
(丁勇, 李清寒, 赵志刚, 杨学军, 陈峰. 有机化学, 2017, 37, 3282.)
[5] Sysak A.; Obmińska-Mrukowicz, B. Eur. J. Med. Chem.,2017, 137, 292.
[6] Walunj Y.; Mhaske P.; Kulkarni, P. Mini-Rev. Org. Chem.,2021, 18, 55.
[7] Zhang Z. C.; Sun Y.; Hua S.; Xu B. L.; Zhang M.; Zhao Q.; Zheng D. D.; Wang Y.; Ju J. F.; Shi Y. J.; Dai, H. Chin. J. Org. Chem.,2023, 43, 1435(in Chinese).
(张紫婵, 孙洋, 华晟, 徐宝琳, 张敏, 赵勤, 郑丹丹, 王杨, 鞠剑峰, 石玉军, 戴红. 有机化学, 2023, 43, 1435.)
[8] Martis G. J.; Gaonkar, S. L. RSC advances,2025, 15, 8213.
[9] Zhu J.; Mo J.; Lin H. Z.; Chen Y.; Sun, H. P. Bioorgan. Med. Chem.,2018, 26, 3065.
[10] Bąchor U.; Brożyna M.; Junka A.; Chmielarz M. R.; Gorczyca D.; Mączyński, M. Int. J. Mol. Sci.,2024, 25, 13618.
[11] Vashisht K.; Sethi P.; Bansal A.; Bansal, P. Vietnam J. Chem.,2025, 63, 195.
[12] Spink E.; Ding D.; Peng Z.; Boudreau M. A.; Leemans E.; Lastochkin E.; Mobashery, S. J. Med. Chem.,2015, 58, 1380.
[13] Boudreau M. A.; Ding D.; Meisel J. E.; Janardhanan J.; Spink E.; Peng Z.; Chang, M. ACS Med. Chem. Lett.,2019, 11, 322.
[14] Huang M. G.; Ruan X. H.; Zhang J. P.; Li Q.; Wang Y. H.; Chen, L. J., Zhang, C.; Li P.; Xue W.Chin. J. Org. Chem., 2017, 37, 2145(in Chinese).
(黄民国, 阮祥辉, 张菊平, 李琴, 王一会, 陈丽娟, 张橙, 李普, 薛伟. 有机化学, 2017,37, 2145.)
[15] Wang J.; Ansari M. F.; Lin J. M.; Zhou, C. H. Chin. J. Chem.,2021, 39, 2251.
[16] Liang C. Q.; Li, Y. M. Chin. J. Chem. Edu.,2019, 40, 1(in Chinese).
(梁楚翘, 李艳梅. 化学教育, 2019, 40, 1.)
[17] Rodriguez J. B.; Gallo-Rodriguez C. ChemMedChem,2019, 14, 190.
[18] Yu H. X.; Yang H.; Shi E. X.; Tang, W. J. Med. in Drug Discov.,2020, 8, 100063.
[19] Yang X. C.; Zeng C. M.; Avula S. R.; Peng X. M.; Geng R. X.; Zhou, C. H. Eur. J. Med. Chem.,2023, 245, 114891.
[20] Yang J. Q.; Zhou X. R.; Chen Y. M.; She, H. X. Chin. J. Org. Chem.,2025, 45, 1306(in Chinese).
(杨家强, 周绪容, 陈阳密, 佘慧娴. 有机化学, 2025, 45, 1306.)
[21] CLSI. CLSI document M100-S28, 2018.
[22] Dong X. T.M.S. Thesis, Zunyi Medical University, Zunyi, 2024(in Chinese).
(董向涛. 硕士论文, 遵义医科大学, 遵义, 2024.)